Approaches using PARP1/2 inhibitors or broad PARP inhibitors have been proposed and tested not only in cancer treatment [98,99,100], but also for non-oncological diseases: for instance, in the protection against oxidative stress, in the suppression of inflammatory responses, in the treatment of ALS and neurodegenerative diseases, and in TDP-43 dependent neurological disorders [194,195,196]. The gene discussed is TARDBP; the disease is neurodegenerative disease.